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Lung carcinoma is the leading cause of cancer-related mortality worldwide. Therefore, numerous studies are focusing on the
assessment of other biological and molecular prognostic factors in these tumors. We evaluated the relationship between 14F7
Mab reactivity, pathological features, DNA-content and S-phase fraction (SPF), and their impact in the survival of NSCLC
patients. Hematoxylin and eosin staining and immunohistochemistry optical microscopy assays as well as DNA content and SPF
measuring using ﬂow cytometry were performed. The 14F7 reactivity was widely observed in NSCLC sections, no depending of
the clinicopathological characteristics. We also obtained diﬀerences in the intensity of reaction with 14F7 as well as in the SPF
between diploid and aneuploid carcinomas. Patients with diploid tumors showing higher SPF and 14F7 reaction joint to a low
mitotic index displayed higher survival rates. Our results are in agreement with the assumption of the possible positive prognostic
value of 14F7 staining in NSCLC.
1.Introduction
Malignant neoplasms of respiratory system are one of the
most common human cancers. Among them, the malig-
nancies of lung have a very poor prognosis, representing
the leading cause of cancer-related mortality worldwide [1].
There are two main variants of the disease, non-small-cell
lung cancer (NSCLC) and small cell lung cancer (SCLC).
NSCLC is the most common form of the disease, accounting
for approximately 85% of all cases [2]. Despite of the recent
advances in cancer therapy, the therapeutic option available
for patients with disease that cannot be surgically managed
has traditionally been limited to chemotherapy, providing a
modest survival beneﬁt [3].
Nowadays, research eﬀorts are focusing on the better
understanding of tumor biology and genetics of lung tumors
in order to select better molecules as target, leading to
more eﬀective treatments for this often diﬃcult disease [3].
Amongthesemolecules,gangliosideshavebeenincluded[4].
Gangliosides are sialic-acid-containing glycosphingolipids
engaged in many biological events that take place at verte-
brate ’ scellmembrane[5].Usually,malignantcellsexpressing
aberrantglycolylatedpatterninthegangliosidescomposition
have been identiﬁed by immunohistochemistry.
It is known that N-acetylneuraminic acid (NeuAc) is
the most abundant sialic acid form expressed in humans.
In contrast to NeuAc, the expression of NeuGc (N-
glycolylneuraminic acid) forming the structure of ganglio-
sides and/or other glycoconjugates (Hanganutziu-Deicher
antigen) has been considered as a tumor-associated antigen
[6]. The aberrant expression of the NeuGc acid residues has
been considered to be related with the altered metabolism of
malignant cells [7–9]. Normal human cells are incapable of
synthesizing NeuGc due to a speciﬁc inactivating mutation2 Pathology Research International
in the cytidine monophospho-N-acetylneuraminic acid
hydroxylase (CMP-NeuAc hydroxylase) gene [10]. The
expression of N-glycolyl-containing gangliosides has been
found in a variety of human malignancies as compared with
normal tissues, with these molecules becoming attractive
targets for cancer immunotherapy [11, 12].
Recently, van Cruijsen et al. published the expression
of N-glycolyl GM3 ganglioside (NeuGcGM3) in non-small-
cell lung cancer using tissue micro array analysis and the
14F7 Mab [13]. 14F7 is the ﬁrst IgG1 highly speciﬁc against
NeuGcGM3 reported in the literature [11]. The present
study was undertaken to evaluate the relationship between
14F7 Mab reactivity, some pathological features, tumour cell
proliferation (S-phase fraction) and DNA content (ploidy)
in NSCLC. We also assessed the prognostic signiﬁcance of
14F7 Mab staining in these patients. In addition, samples
of nasopharyngeal carcinoma as well as normal and nontu-
moral tissues sections were included in this study.
2.MaterialsandMethods
We used the 14F7 Mab, a murine IgG1 highly speciﬁc against
the variant N-glycolylated of GM3 ganglioside. 14F7 Mab
was produced by the Center of Molecular Immunology,
Havana, Cuba as it was previously described [11].
2.1. Tissue Specimens and Previous Processing. An u m b e ro f
14 and 32 routinely processed, formalin-ﬁxed and paraﬃn-
embedded archival samples with diagnosis of nasopharyn-
geal carcinoma and lung cancer, respectively, as well as
3 cases of nontumoral entities of nasopharynx and 4 of
normal human lung were taken from both the Pathology
Department of Manuel Fajardo General Hospital and the
Tumor Bank of the Center of Molecular Immunology, after
obtaining informed consent and the approval consent by
the institutional ethical committees. Five micrometer serial
sections from each block were obtained in a micrometer
(Leitz 1512, Germany) and mounted on plus slides (Dako
S2024, Carpinteria, USA). All sections were attached to the
slide by heating in a 70◦C oven for 1h. Afterward the slides
were kept at room temperature until they were used.
The slides were dewaxed in xylene and rehydrated in
graded ethanol series as usually and endogenous peroxidase
activity was blocked with dual endogenous enzyme block
solution (Dako S2003, Carpinteria, USA) for 10 minutes. All
sections were washed in distilled water for 10 minutes and
rinsed with washing buﬀer (Dako K1494, Carpinteria, USA).
2.2. Immunohistochemical Staining. Subsequently, slides
were placed in a humid chamber and incubated with the pri-
mary mouse anti-NeuGcGM3 ganglioside 14F7 Mab for 1h
atroomtemperature.Negativecontrolswereperformedsub-
stitutingprimaryantibodyforwashingbuﬀerandsectionsof
colonic adenocarcinoma were taken as positive control [14].
After two rinses in washing solution the slides were incu-
bated with a polymer/HRP (Dako E0354, Carpinteria, USA)
for 30 minutes each one. Between incubations, slides were
washed for 10 minutes. Afterward, enzymatic activity was
visualized with DAB substrate chromogen solution (Dako
K3465, Carpinteria, USA) and the tissues were counter-
stainedwithMayer’sHematoxylin(DakoS2020,Carpinteria,
USA). The samples were dehydrated and mounted with a
synthetic medium (Sakura 1467, Finetek Europe B.V).
2.3. Immunohistochemical Evaluation. The intensity of reac-
tion of each samples was judged as negative (−), weak
(+), moderate (++), and strong (+++), and combinations
of these patterns were used to express intermediate levels
of immunostaining. Additionally, the most representative
regions of each section were selected and the percentage
of tumor cells showing 14F7 Mab staining in them was
estimated using the 10x objective lens. It was classiﬁed as 0
(negative to less than 5%), 1+ (6–25%), 2+ (26–50%), and
3+ (more than 50%). The results in agreement with two
observers were considered as ﬁnal.
2.4. Pathological Features Evaluation. Tumor sections were
stained with hematoxylin and eosin (HE). Morphologic
parameters such as histopathological classiﬁcation, grade of
diﬀerentiation,degreeofcellularpleomorphism,andmitotic
andnecrosisindexeswereevaluatedforanexpertpathologist
(Charles E. Rengifo) in each tumor tissues.
The cytomorphologic characteristics such as cell and
nuclear size, cellular shape, chromatin pattern, nucleoli, and
amount of cytoplasm was evaluated to express the degree of
cell pleomorphism and was scored as follows: 0 (no evident
cell pleomorphism) 1, (low), 2 (moderate), and 3 (high)
cell pleomorphism. Mitotic index was recorded qualitatively
and was expressed as was previously described for degree of
cell pleomorphism. The degree of tumor necrosis (necrosis
index) on the section was determinated using a low-power
ﬁeld (10x objective lens) and was scored subjectively as
follows: 0 (no necrosis), 1 (less than 50% of necrosis areas
per ﬁeld), and 2 (more than 50% of necrosis areas per ﬁeld).
2.5. Flow Cytometric DNA-Content Measurement. The
method as was previously described [15]w i t hs o m e
modiﬁcations was performed. Brieﬂy, we evaluated the
DNA content (ploidy) and the proliferative characteristics
(percentage of cells in S-phase) by the application of ﬂow
cytometry methodology (FCM) using nuclei isolated from
formalin-ﬁxed and paraﬃn-embedded tissues.
When possible, samples with no or minimal tumor
necrosis were studied. Two or three 50µms e c t i o n sw e r e
obtainedfromeachtissueblock.Afterward,thesampleswere
dewaxed in xylene, rehydrated in a series of progressively
decreasing concentrations of ethanol and ﬁnally washed in
distilledwater.Thetissuesweretreatedwith0.2%citrateacid
pH6 solution for 2h at 80◦C. Single-cell suspensions were
thenpreparedbyincubationat37◦Cfor10minutesina0.5%
pepsin solution (Sigma Chemical Co., St. Louis, MO) (pH
1.5). After the enzymatic digestion by pepsin, disaggregation
was completed mechanically. Disaggregated material was
ﬁltered through 50µm nylon mesh and routinely washed.
Dissociated nuclei were adjusted to a ﬁnal concentration of
1 × l06 nuclei/mL and were then stained with propidiumPathology Research International 3
iodideataﬁnalconcentrationof40µm/mL(SigmaChemical
Co., St. Louis, MO). The samples were analyzed on an
Ortho Cytoron Absolute ﬂow cytometer (Ortho Diagnostic
Systems, Tokyo, Japan) equipped with a 15MW argon laser.
An average of 10.000 nuclei was evaluated for each sample, at
a low ﬂow rate. Afterward, the data obtained were analyzed
using ModFit LT software (DNA Modeling System) version
2.0 (Verity Software House, Inc.). A sample was considered
DNA diploid if, on the histogram, there was a single peak in
theG0/G1 phaseandDNAaneuploid,iftherewasatleastone
distant G0/G1 population. Tetraploid as well as multiploid
histograms were classiﬁed into the aneuploid group.
2.6. Statistical Analysis. Statistical analysis was performed
with nonparametric tests, since the distribution of 14F7
Mab reactivity in NSCLC was nonnormal. The correlation
between pathological variables and the intensity of reaction
with 14F7 Mab as well as the percentages of positive cells
was assessed by Spearman ranks correlation coeﬃcients.
Chi-square test was used to compare dichotomic variables.
Survival distribution was estimated by the Kaplan-Meier
method. Survival comparison was performed by two-sided
log-rank tests. The criterion for statistical signiﬁcance was
P<0.05.
3. Results
3.1. Patient Description and Pathological Features. Table 1
showed a summary of patient characteristics and some path-
ological features. The median of patient age at presentation
was 55 years (ranged from 41 to 74 years). Median overall
survival of the population was 64.06 months (ranged from 3
to 91.29 months).
3.2. Higher Levels of 14F7 Mab Reactivity Were Detected in
Non-Small-Cell Lung Cancer Sections. Firstly, we evaluated
the immunohistochemical localization of cytokeratin in
order to verify the quality of the formalin-ﬁxed and paraﬃn-
embedded tissues. The samples remained well preserved,
conserving intact the molecular antigenic determinants and
showing a good morphology (Figure 1).
No staining with 14F7 Mab was observed in normal lung
sections (0/4). However, the reactivity of 14F7 Mab was evi-
denced in 29/31 (93.5%) of lung cancer samples not taking
into account the type of carcinoma (Table 2). The intensity
of reaction of 14F7 Mab varied from weak to intense,
but 25/29 (86.2%) of lung carcinomas showed a moder-
ate-to-intense recognition. On the other hand, more than
25% of malignant cells were reactive with 14F7 Mab in 27/29
(93.1%) of tumors. The pattern of staining of 14F7 Mab was
ﬁnely granular and was located on both cell membrane and
cytoplasm of malignant cells, although the cytoplasmatic pa-
ttern was mainly detected (Figure 2). No nuclear reactivity
with 14F7 Mab was evidenced.
3.3. The 14F7 Mab Recognition Was Not Related with the
Pathological Features of Patients. No correlation was ob-
served between the intensity of 14F7 Mab reaction and the
Table 1: Patient characteristic and pathological features.
Features No. (%)
Gender
Female 9/32 (28.1)
Male 23/32 (71.9)
Age (years)
<60 21/32 (65.7)
60–70 6/32 (18.7)
>70 5/32 (15.6)
Tumor size (cm)
<3 6/32 (18.7)
>3 26/32 (81.3)
Tumor stage
I 16/32 (50.0)
II 7/32 (21.9)
III A 2/32 (6.3)
III B 1/32 (3.1)
IV 6/32 (18.7)
Histopathological type
Squamous cell carcinoma 12/32 (37.5)
Adenocarcinoma 9/32 (28.1)
Large cell carcinoma 9/32 (28.1)
Other 2/32 (6.3)
Grade of diﬀerentiation
Well 3/32 (9.4)
Moderate 13/32 (40.6)
Poor 14/32 (43.7)
Undiﬀerentiated 2/32 (6.3)
Degree of cell pleomorphism
No evident 3/32 (9.4)
Low 10/32 (31.2)
Moderate 11/32 (34.4)
High 8/32 (25.0)
Necrosis index
No evident 9/32 (28.1)
<50% 12/32 (37.5)
>50% 11/32 (34.4)
Mitotic index
No evident 2/32 (6.3)
Low 10/32 (31.2)
Moderate 15/32 (46.9)
High 5/32 (15.6)
No. Number of cases, % percentages.
percentage of positive cell with the distribution of gender,
age, tumor size, tumor stage, histopathological type, grade of
diﬀerentiation, nor necrosis index. Interestingly, a noticeable
correlationwasdetectedbetweenthepercentageof14F7Mab
positive cells and the degree of cell pleomorphism (P =
0.0001), but not with the intensity of reaction (P = 0.0713)
(Table 3).
3.4.DNAContent,MitoticIndexandDiploidS-PhaseFraction
Correlate with the 14F7 Mab Staining. Flow cytometry4 Pathology Research International
(a) (b)
(c) (d)
Figure 1: Microphotographs of poorly diﬀerentiated adenocarcinoma of the lung. (a) Hematoxylin and eosin coloration. Immuno-
histochemical localization of cytokeratin was performed to verify the quality of the formalin-ﬁxed and paraﬃn-embedded tissues. (b)
Conventional immunoperoxidase techique counterstaining with Mayer’s Hematoxylin. Black bar = 50µm. (c) and (d) Conventional
ﬂuorescent and confocal microscopy, respectively. FITC-labeled cytokeratin (green signal) was used. Nuclei were contrasted with propidium
iodide (red signal) (40 and 100x magniﬁcation, resp.).
Table 2: Immunoreactivity of the 14F7 Mab in normal tissue and lung carcinoma samples.
Histopathological classiﬁcation 14F7 Mab reactivity
No. (%) Intensity range % of Positive cells
Normal tissues 0/4 (0) − 0
Non-small-cell lung cancer 26/28 (92.9%)
Squamous cell carcinoma 10/10 (100) +/+++ 1–3
Adenocarcinoma 8/9 (88.8) ++/+++ 2/3
Large cell carcinoma 6/7 (85.7) +/+++ 2/3
Others 2/2 (100) ++/+++ 1/3
Small cell carcinoma 3/3 (100) +/+++ 2/3
Intensity: − negative, + weak, ++ moderate, +++ intense. Positive cells: 0 (negative to less than 5%), 1 (6–25%), 2 (26–50%) and 3 (more than 50%).
analysis for DNA content was performed in 20/32 (62.5%)
non-small-cell lung cancer samples. Eleven (55.0%) were
diploid and 9 (45.0%) aneuploid. The median coeﬃcient
of variation (CV) was 7.4 (range 3.9–13.89) (Figure 3). A
signiﬁcant correlation was detected between the intensity
of reaction of 14F7 Mab and the ploidy status (P =
0.0289, rs =− 0.4658; Spearman test) but not, when the
percentage of cells showing 14F7 Mab staining was evaluated
(Tables 4 and 5). When the intensity of reaction of 14F7
Mab in tumors with diploid and aneuploid status was
compared, a statistically signiﬁcant diﬀerence was observed
(P = 0.0176, Chi-square test). In aneuploid tumors, no
correlation with the S-phase fraction (SPF) was observed.
Nevertheless, in diploid tumors, the intensity of reaction
of 14F7 Mab correlate with the SPF (P = 0.0208, rs =
0.5126;Spearmantest).DiploidtumorswithhigherSPFwerePathology Research International 5
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Figure 2: Hematoxylin and eosin staining of squamous (a), adenosquamous (c), and large cell carcinoma of the lung (f). See, the intense
reaction of 14F7 Mab mainly located in cell membrane and also in the cytoplasm of malignant epithelial cells of squamous (b) and
adenosquamous carcinomas (d). A moderate immunostaining with 14F7 Mab is showed in large cell carcinoma (f). Black bar = 50µm.
mostlyrecognizedby14F7Mab.However,nocorrelationwas
obtained when the percentage of 14F7 Mab positive cells was
studied. Interestingly, aneuploid tumors displayed higher S-
phase fraction than diploid ones (P = 0.0010, Chi-square
test). By the contrary, lung tumors with higher mitotic index
showed a reduction in the intensity of reaction with 14F7
Mab (P = 0.0284; rs =− 0.4143; Spearman test) (Table 6).
No correlation was observed when the percentage of positive
cells was analyzed (Table 4).
3.5. Overall Survival of Patient Was Strongly Associated to the
Intensity of Reaction with 14F7 Mab, but Not with Ploidy.
The intensity of 14F7 Mab was strongly associated with
overall survival of patient (P = 0.0125, Log rank test).
Statistical signiﬁcant diﬀerences were detected when the
weak intensity of reaction was compared with moderate and
intense patterns (P = 0.0028 and P = 0.0423; Log rank
test, resp.). However, no diﬀerence was observed between
moderate and intense patterns of intensity (P = 0.9824; Log6 Pathology Research International
Table 3: Correlation between pathological features and 14F7 Mab immunorecognition in non-small-cell lung carcinoma.
Pathological features
14F7 Mab reactivity
No. Intensity of reaction % of positive cells
P value P value
Gender 28 0.1723 0.1152
Age 28 0.8443 0.6818
Tumor size 28 0.7052 0.8801
Tumor stage 28 0.3797 0.0760
Type of carcinoma 28 0.7786 0.9090
Grade of diﬀerentiation 28 0.3155 0.3192
Degree of pleomorphism 28 0.0713 0.0001
Necrotic index 28 0.2021 0.1804
No. Number of cases, % percentages, P value using Spearman correlation test.
rank test) (Figure 4). Ploidy was not found to be associated
with the overall survival of NSCLC patient (P = 0.0692; Log
rank test) (Figure 5).
3.6. The 14F7 Mab Immunorecognition Was Also Observed
in Nasopharyngeal Carcinomas. Normal tissues (0/2) were
not stained with 14F7 Mab. However, a weak immunorecog-
nition of 14F7 Mab was detected in more than 50% of
nasopharyngeal dysplastic cells (1/1). In addition, a weak-to-
moderate reaction was observed in in situ carcinoma (2/2).
Concerning to nasopharyngeal carcinoma, 13/14 (92.8%)
of them were recognized by 14F7 Mab not taking into
accountthegradeofdiﬀerentiation.Thereactionwaslocated
mainly on the plasmatic membrane of malignant epithe-
lial cells, although a cytoplasmatic pattern was evidenced
(Table 7, Figure 6). No statistically signiﬁcant diﬀerence was
evidenced when the intense of reaction of 14F7 Mab in lung
squamous cell carcinoma and nasopharyngeal carcinoma
were compared (P = 0.5743, Chi-square test).
4. Discussion
Up to date, TNM staging after surgery is considered the most
importantprognosticfactorinpatientswithNSCLC[16,17].
However, the pathology-based TNM stage classiﬁcation has
been considered to provide imprecise information about the
survival rates [18]. In consequence, numerous studies are
currently focusing in the evaluation of other biological and
molecular prognostic factors [3, 19].
In this study, we show the immunoreactivity of 14F7
Mab, an IgG1 highly speciﬁc raised against N-glycolyl GM3
ganglioside, in almost all NSCLC sections, not depending
on age, gender, tumor size, tumor stage, histopathological
classiﬁcation, grade of diﬀerentiation, and necrosis index.
The patter of staining was ﬁnely granular and was localized
inbothcellmembraneandcytoplasmofmalignantepithelial
cells as it was previously described [13, 14, 20, 21].
The role of NeuGcGM3 ganglioside in tumoral progres-
sion as well as its suppressor properties has been previously
reported [22, 23]. The expression of NeuGcGM3 has been
considered responsible of tumor-induced dendritic cells
(DCs) suppression in NSCLC patient. NeuGcGM3 inhibit
DCs diﬀerentiation, maturation, and migration based in the
inverse correlation observed between NeuGcGM3 expres-
sion and inﬁltrating mature dendritic cells. Conversely, the
expression of this ganglioside has been associated with a
favorable survival in NSCLC patients, suggesting its prog-
nostic value [13]. Here, we observed a strong association
between the higher levels of the 14F7 Mab immunorecog-
nition and increased overall survival rates. Patients with a
low intensity of reaction with 14F7 Mab showed a poorer
overall survival as compared with those that were intense
recognized by 14F7 Mab. Our results are in agreement with
thosedescribedbyvanCruijsenetal.concerningtoapositive
prognostic factor of 14F7 Mab staining in NSCLC patient
[13]. However, NeuGcGM3 expression was associated with
a more aggressive biological behavior in neuroectodermal
tumors [24].
Both the proliferative activity of tumor cells and mitosis
count has been considered as potential prognostic factors in
lung cancer [25, 26]. Here, we found a positive association
between the intensity of reaction of 14F7 Mab and the
proliferation index (S-phase fraction) in diploid NSCLC
but not in aneuploid tumors, measured by ﬂow cytometry
technology. Nevertheless, the mitotic index observed in
these samples showed a negative association with the 14F7
Mab staining. The eﬀects of the N-acetyl variant of GM3
ganglioside in the cell cycle have been previously reported.
GM3 inhibit cancer cell proliferation by modulating the
expression of cell cycle regulation proteins. GM3 dramat-
ically increases cyclin-dependent kinase (CDK) inhibitor
p21WAF1 expression throughtheaccumulationofp53 protein
by the PTEN-mediated inhibition of the PI-3K/AKT [27].
PTEN also resulted in the inhibition of cell cycle progression
through the CDK inhibitor p27kip1 [28]. Previously, no
signiﬁcant correlation between the percentage of positive
cells for the Ki-67 proliferating antigen and the expression
of NeuGcGM3 was detected [24]. Although, it is known that
the nuclear antigen recognized by Ki-67 antibody provides
a reliable method for evaluating tumor growth fraction in
lung cancer, it is expressed during the G1,S ,G 2,a n dM
phases of the cell cycle [29] making impossible to distinguish
between S-phase and mitosis. However, the relation betweenPathology Research International 7
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Figure 3: DNA-content (ploidy) analysis in non-small-cell lung carcinoma samples measured by the ﬂow cytometric proﬁle and analyzed by
ModﬁtLTsoftware.CellspreparedbytheHedleymethod[15]andstainedwithpropidiumiodide.DNAhistogramsofdiploid(a),aneuploid
(b), multiploid (c), and tetraploid (d) tumors.
Table 4: Correlation between proliferation features and 14F7 Mab staining in non-small-cell lung carcinoma.
Proliferation features
14F7 Mab reactivity
No. Intensity of reaction % of positive cells
P value P value
DNA content (ploidy) 22 0.0289 0.3065
S-phase fraction (SPF) diploid 20 0.0208 0.2319
S-phase fraction (SPF) aneuploid 20 0.0651 0.4226
Mitotic index 28 0.0284 0.3147
No. Number of cases, % percentages, P value using Spearman correlation test.8 Pathology Research International
Table 5: Relation between DNA content (ploidy) and 14F7 Mab reactivity in non-small-cell lung carcinoma.
14F7 Mab reactivity
Ploidy
Diploid Aneuploid Spearman
N o .( % ) N o .( % ) P value rs
Intensity of reaction 0.0289 −0.4658
Negative 0/11 (0) 2/9 (22.2)
Weak 0/11 (0) 2/9 (22.2)
Moderate 3/11(27.3) 2/9 (22.2)
Intense 8/11 (72.7) 3/9 (33.3)
Total 11/11 (100) 7/9(77.7)
No. Number of cases, % percentages, P value using Spearman correlation test, rs Spearman correlation coeﬃcient.
Table 6: Relation between S-phase fraction and mitotic index with the 14F7 Mab immunoreactivity in diploid non-small-cell lung
carcinoma.
Proliferation rates
14F7 Mab reactivity
Negative Weak Moderate Intense Spearman correlation
No. (%) No. (%) No. (%) No. (%) P value rs
S-phase fraction (SPF) 0.0208 0.5126
0–5 — — — —
6–25 — 3 (27.3) — —
26–50 — — 6 (54.5) —
>50 — — — 2 (18.2)
Total 0 3(27.3) 6 (54.5) 2(18.2)
Mitotic index 0.0284 −0.4143
No evident — — — 2 (7.1)
Low 1 (3.6) — 2 (7.1) 6 (21.4)
Moderate 1 (3.6) 2 (7.1) 7 (25.0) 3 (10.7)
High — 1 (3.6) 2 (7.1) 1 (3.6)
Total 2(7.1) 3(10.7) 11 (39.3) 12(42.8)
No. Number of cases, % percentages, P value using Spearman correlation test, rs Spearman correlation coeﬃcient.
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Figure 4: Kaplan-Meier estimate of overall survival among NSCLC
patients showing diﬀerent intensities of reaction with 14F7 Mab
(P = 0.0125, Log rank test).
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Figure 5: Kaplan-Meier estimate of overall survival among NSCLC
patients showing diploid and aneuploid DNA-content status (P =
0.0692; Log rank test).Pathology Research International 9
Table 7: Immunorecognition of 14F7 Mab in nontumoral and nasopharyngeal carcinoma.
Histopathological classiﬁcation 14F7 Mab reactivity
No. of cases (%) Intensity range % of positive cells
Nontumoral tissues
Normal 0/2 (0) −−
Dysplasia 1/1 (100) + 3
Squamous cell carcinoma (SCC)
In situ 2/2 (100) +/++ 1/3
Well 4/4 (100) ++/+++ 1–3
Moderately 3/3 (100) +/+++ 1–3
Poorly 5/6 (83.3) +/++/+++ 1–3
Undiﬀerentiated 1/1 (100) +++ 3
Total (SCC) 13/14 (92.8)
Intensity: − negative, + weak, ++ moderate, +++ intense. Positive cells: 0 (negative to less than 5%), 1 (6–25%), 2 (26–50%) and 3 (more than 50%).
50 µm
(a)
50 µm
(b)
Figure 6: Hematoxylin and eosin staining of poorly diﬀerentiated nasopharyngeal carcinoma (a). Note: a strong and ﬁnely granular
immunoreactivity of 14F7 Mab mainly located in cell membrane of malignant cells (b). Black bar = 50µm.
p53 oncoprotein and NeuGcGM3 ganglioside expressions
have been previously published [30]. These results permit us
toconsiderapossiblecellcycleinhibitoryeﬀectoftheantigen
recognized by 14F7 Mab in malignant cells, probably similar
to that induced by GM3. Interestingly, the only structural
diﬀerence between N-acetyl and N-glycolyl neuraminic acid
is a single-oxygen atom at the C-5 position of NeuGc.
Therefore, experiments looking for the possible relation
between the 14F7 Mab recognition and the expression of
PTEN, p53, and CDK proteins are ongoing in our lab.
On the other hand, investigations regarding the prognos-
tic value of ploidy have been greatly facilitated by the appli-
cation of ﬂow cytometry using nuclei isolated from paraﬃn-
embedded tissues [26]. DNA-content (ploidy) abnormali-
ties have been considered as a heterogeneous spectrum of
impaired tumor cell DNA histogram patterns. The p53 tum-
orsuppressor geneinvolved in thearrest of cellgrowth is also
related with DNA repair in response to DNA damage [31].
In our study, the intensity of reaction with 14F7 Mab showed
statistical signiﬁcant diﬀerences when diploid and aneuploid
NSCLC were compared. Tumors with diploid status were
mostly reactive with 14F7 Mab, while aneuploid samples
displayedhigherlevelsofS-phasefraction.Curiously,tumors
with increased 14F7 Mab intensity of reaction also exhibited
a decreased in the mitotic index.
A highly signiﬁcant relationship between ploidy and Ki-
67 has been previously reported [32]. In a similar study,
Pence et al. as well as, Ludovini et al. found a higher Ki-67
immunostaining in aneuploid tumors; however, no associa-
tion between DNA content and Ki-67 expression was
detected [29, 33]. In addition, we found a trend for an asso-
ciation between aneuploidy status and poor overall survival
in NSCLC, although no signiﬁcant diﬀerence was obtained.
However, the disturbed cellular DNA-content resulting from
increased genomic instability have been associated with poor
prognosis in lung carcinomas, the negative eﬀects of aneu-
ploidy in the overall survival of patient with NSCLC still re-
main controversial [29, 34].
Tumor necrosis is considered a consequence of chronic
cellular hypoxia and has been considered an adverse risk
factor for survival and recurrence in patients with NSCLC
[35] leading to a more aggressive tumour phenotype and10 Pathology Research International
to a poor prognosis [36]. It is known that malignant cells
displaysomegeneticchangesthatpermitthemtosurviveand
even proliferate in a hypoxic environment. Tumor hypoxia
induces the transcription in the cells of a sialic acid trans-
porterfacilitatingtheincorporationofNeuGcmoleculefrom
the external medium to the gangliosides [37]. In this study,
no correlation was observed when the 14F7 Mab reactivity
and the necrosis index were compared. However, the expres-
sion of NeuGc-containing gangliosides (e.g., NeuGcGM2) in
some tumors has been associated with tumor hypoxia [37].
As it was previously described, gangliosides are compo-
nentsofeukaryoticcellmembranes[38],structureintimately
related to cell morphology [39]. While GM3 is a normal con-
stituentoftheplasmaticmembraneofthemajorityofhuman
cells [40], the diﬀerence between N-acetyl and N-glycolyl
neuraminic acid [41] has converted NeuGcGM3 in a tumor-
associated antigen [42]. Here we found a relation between
the number of 14F7-Mab-positive cells and the degree of cell
pleomorphisminNSCLCsections.ThereactivityofthisMab
was evidenced in cell membrane and also in the cytoplasm of
the malignant cells. The decreasing synthesis of ganglioside
GM3 has been associated with a variety of changes in a
number of processes that involve the actin cytoskeleton
[43]. Interestingly, the primary intracellular determinant of
cell morphology is precisely the cytoskeleton [39]. Previous
reports have suggested a strong connection between both N-
acetyl [44]a n dN - G l y c o l y l[ 45] function of GM3 ganglio-
sides and actin ﬁlaments. Aberrant expression of the antigen
recognized by 14F7 Mab seems to be in relationship with
some changes in the morphology of the malignant cells.
Nasopharyngeal carcinoma (NPC) is a squamous cell
carcinoma that commonly aﬀects certain geographic areas,
such as southern Asia. A variety of molecules have been
evaluated in NPC in order to consider them as potential
target for novel treatments due to a number of molecular
abnormalities characteristic of NPC [46]. Almost all NPCs
at this serie were recognized by 14F7 Mab not taking into
accountthegradeofdiﬀerentiation,similartothoseobtained
in lung squamous cell carcinomas. To our knowledge, it is
the ﬁrst report in the literature about the 14F7 Mab staining
in NPC. The expression of other N-glycolyl neuraminic acid
containingglycoconjugateonthecellsurfaceofNPCsections
using membrane immunoﬂuorescence staining with chicken
antiserum against N-glycolylneuraminyl- lactosylceramide
(HD3) has been previously reported [6]. Curiously, some
alterations in the cellular proliferation pathways such as the
AKT pathway and mitogen-activated protein kinases joint
t oa b e r r a t i o n si nc e l lc y c l ei n v o l v i n gf a c t o r ss u c ha sp 1 6a n d
CDKs have been found in NPC [46]. Experiments looking
forward the possible prognostic factor of 14F7 Mab in NPC
immunostaining should be designed by our group.
Encouraging results have been obtained in NSCLC
patient using molecular cancer vaccines. Hern´ andez et al.
reported the immune response against NeuGcGM3 in
NSCLC patients treated with 1E10 (an anti-idiotypic Mab
that mimicry NeuGcGM3). Patient immune sera were
able to induce complement-independent cell death of
NeuGcGM3-expressing X63 murine myeloma target cells
[4]. Interestingly, the ability of 14F7 Mab to directly kill
the NeuGcGM3-positive murine myeloma cells without
participation of complement have been previously reported
[45, 47]. Moreover, the passive treatment with 14F7 Mab
produces a strong suppression of tumor growth, similar
to the antitumoral response obtained with standard
chemotherapy treatment [47]. Fortunately, patients that
developed an immune response against NeuGcGM3 showed
longer median survival times [4].
In summary, we are showing the immunoreactivity of
14F7 Mab, a highly speciﬁc IgG1 raised against NeuGcGM3
in a serie of non-small-cell lung carcinoma as well as in
nasopharyngeal carcinoma. The relation between the inten-
sity of reaction with 14F7 Mab and a higher overall survival
rates in diploid NSCLC joint to a decreased mitotic index in
thesepatientspermitustosupporttheantigenrecognized by
14F7Mabasagoodprognosticfactorinthesepatients.Addi-
tionally, we described diﬀerences in the intensity of reaction
with 14F7 Mab between diploid and aneuploid carcinomas,
although we could not establish diﬀerences in the overall
survival between diploid and aneuploid tumors. Our data
also support the continuous use of anti-NeuGc therapy in
NSCLC patient due to a higher reactivity observed with 14F7
Mab. Experiments looking for a better understating of the
possible mechanisms involved in these results are ongoing
in our group. Simultaneously, a phase III clinical trial in
NSCLC patient using the 1E10 molecular cancer vaccine had
started in our country. In addition, experiments looking for
a chimerical and/or humanized counterpart of the murine
14F7 Mab as well as their evaluation are in progress.
5. Conclusions
The high expression of NeuGcGM3 as recognized by 14F7
Mab in NSCLC as well as in nasopharyngeal carcinoma,
but not in sections, supports the continuous use of this
molecule as target in the immunotherapy of NSCLC patient
and opens up this possibility in nasopharyngeal carcinoma.
Thestainingwith14F7MabinNSCLCisinrelationshipwith
higher overall survival of patients, constituting a positive
prognostic factor.
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